BEIJING, April 30, 2026 — Byongen Therapeutics, an innovative biotechnology company dedicated to next-generation viral vector engineering, today announced that it has been selected to present one oral presentation and four poster presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 11–15, 2026, in Boston, MA.
The presentations will showcase Byongen’s advancements in AAV capsid directed evolution. The oral presentation will feature a novel muscle-targeting motif identified through a non-human primate (NHP) in vivo screening, demonstrating significant potential for clinical translation. Additionally, four posters will detail the company’s proprietary DynEvoLib® capsid discovery platform and its technological solutions to industry R&D bottlenecks.
📢Oral Presentation: Discovery of a Novel Muscle-Targeting Motif
• Title: Directed Evolution in Nonhuman Primates Identifies AAV Capsids with a Novel Motif Enabling Efficient Muscle Targeting with Reduced Liver Tropism
• Core Highlights: This study describes the discovery of a novel AAV capsid motif through NHP in vivo screening. The identified motif demonstrates superior muscle transduction efficiency and precise targeting, enabling potent delivery while minimizing off-target liver expression.
• Abstract ID: 312
• Presentation Time: May 14, 10:15 AM (EDT)
📌Poster Presentations: DynEvoLib® Platform Technologies (May 12–14)
1. PEARS (Rational Design / #2029): Integrates randomization with cell-surface structural information to enhance the precision of AAV library design.
2. CAPTURE (Sensitive Detection / #2025): Addresses the bottleneck of sparse signal extraction in vivo, supporting high-throughput processing of gram-level tissue samples while enhancing sensitivity and maintaining fidelity.
3. CALIBRATOR (Data Calibration / #1025): Utilizes in vivo reference standards for absolute quantification, ensuring precise data alignment to improve variant evaluation accuracy.
4. CAMEL (Multi-level Validation / #3028): Enables parallel in vivo validation of AAV variants across DNA, mRNA, and protein levels within a single animal.
About the ASGCT Annual Meeting
The American Society of Gene & Cell Therapy (ASGCT) Annual Meeting is the world’s largest and most influential professional event in the field of gene and cell therapy. The 29th Annual Meeting brings together global scientists, clinicians, and industry experts to discuss the latest breakthroughs in the field.
About Byongen Therapeutics
Byongen Therapeutics is a biotechnology company focused on original innovation in AAV delivery technologies. The company aims to address core clinical delivery bottlenecks through capsid engineering. By leveraging its proprietary DynEvoLib® platform, Byongen integrates AI, rational design, and high-throughput directed evolution to develop next-generation AAV capsids. Byongen’s R&D focus targets the development of specialized capsids for neuromuscular and central nervous system (CNS) diseases.
京公网安备11011502040057号
